News | October 09, 2024
Briefs: NATCO Pharma, Mylan Pharmaceuticals, Novo Nordisk and Alembic Pharmaceuticals
Mylan and Novo Nordisk reach settlement of US patent litigation related to Ozempic
Mylan and Novo Nordisk reach settlement of US patent litigation related to Ozempic
The acquisition will strengthen the overall company’s position as leading global CRO services partner
MNI is dedicated to developing and offering phytochemical (plant-based) products and healthcare solutions, aimed at treating metabolic syndrome
Based on ECHO Phase III trial which demonstrated Calquence combination reduced risk of disease progression or death by 27% compared to standard-of-care chemoimmunotherapy
USFDA completes PAI of Lupin’s biotech facility in Pune
Emcure will play a crucial role in ensuring the availability of high-quality, low-cost versions of lenacapavir in 120 countries
Expansion includes a new 5-story, 136k sq. ft. multipurpose building in Sejong
Grant funding from the Bill & Melinda Gates Foundation will support the rapid and efficient design and synthesis of novel small molecules
The inspection conducted by EDQM at its Visakhapatnam facility
Sun Pharma will have the exclusive worldwide rights to commercialise Fibromun
Subscribe To Our Newsletter & Stay Updated
